Tokai Pharmaceuticals is focused on developing new treatments for prostate cancer. The company's lead drug candidate, galeterone (TOK-001), is currently being evaluated in a Phase 2 study, ARMOR2, in patients with castration resistant prostate cancer (CRPC) as part of the ARMOR clinical development program.
